RxDoctor Payments Data

Kyle Graper, MD

Family Medicine · Crawfordsville, INNPI 1790123891

Payments from drug & device makers

$317in general payments, 2019–2025

Across 17 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$197
  • Sunovion Pharmaceuticals Inc.$57
  • AbbVie$26
  • Pfizer$13
  • GSK$12
  • AstraZeneca$12

What the payments were for

  • Food & beverage$30696%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$197
Sunovion Pharmaceuticals Inc.1$57
AbbVie2$26
Pfizer1$13
GSK1$12
AstraZeneca1$12

How this compares

$317 in reported general payments places this provider in the 40th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$205,952
Medicare patients
482
Services billed
3,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin271$348,251
EliquisApixaban186$241,407
TrulicityDulaglutide110$187,978
Trelegy ElliptaFluticasone/Umeclidin/Vilanter129$132,879
OzempicSemaglutide98$115,080
MounjaroTirzepatide96$108,061
JanuviaSitagliptin Phosphate81$105,611
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr106$61,609
XareltoRivaroxaban32$43,458
FarxigaDapagliflozin Propanediol30$43,112
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$41,120
VascepaIcosapent Ethyl28$26,245
Breo ElliptaFluticasone/Vilanterol38$24,606
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$24,463
LinzessLinaclotide20$20,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$241,407186 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$12$219,094273 claims
Novo NordiskOzempic$197$115,08098 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$12$67,28367 claims
AbbVieLinzess, Creon$26$34,69332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Crawfordsville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →